NCT01018693

A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance

Randomized, Double-blind, Placebo-controlled Trial to Determine the Capacity of VAK694 to Elicit Long Term Immune Tolerance When Combined With Subcutaneous Allergen Immunotherapy for the Treatment of Seasonal Allergic Rhinitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine whether VAK694 when combined with subcutaneous immunotherapy leads to long term immune tolerance to allergen in individuals with seasonal allergic rhinitis.

Conditions

• Seasonal Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	VAK694; Alutard Avanz SQ
DRUG	VAK694 placebo infusion; Alutard Avanz SQ
DRUG	VAK694 placebo infusion; Saline

Timeline

• Start date: 2009-11-01
• Primary completion: 2011-10-01
• Completion: 2011-10-01
• First posted: 2009-11-25
• Last updated: 2017-03-21

Locations

1 site across 1 country: United Kingdom